Global Humira Market Size To Exceed USD 15.71 Billion By 2035 | CAGR 5.09%
Category: HealthcareGlobal Humira Market Size To Exceed USD 15.71 Billion By 2035 | CAGR 5.09%
According to a Research Report Published By Spherical Insights & Consulting, The Global Humira Market Size is Expected to Grow from USD 9.10 Billion in 2024 to USD 15.71 Billion By 2035, at a CAGR of 5.09% during the Forecast Period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 245 pages with 120 Market data tables and figures & charts from the report on the " Global Humira Market Size, Share, and COVID-19 Impact Analysis, By Product (Branded and Biosimilar), By Application (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Crohn’s Disease (CD), Ulcerative Colitis (UC), Ankylosing Spondylitis and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/humira-market
The Humira Market Size is the Worldwide Market for Humira (adalimumab), which is a biologic drug designed by AbbVie, mainly for the treatment of multiple autoimmune conditions. Moreover, humira's success in treating a wide variety of autoimmune diseases, like rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis, is a major force behind its market expansion. Its capacity to mitigate inflammation, provide symptom relief, and retard disease progression in several indications solidifies its status as a go-to treatment. Humira has established significant brand recognition through its over 20 years in the market. The confidence patients and healthcare professionals have in the drug's consistent outcomes drives its market strength. Doctors continue to favor Humira for its tested and trusted efficacy. However, humira is still among the costliest biologics available, and that restricts access to some patients. Even with insurance, the steep out-of-pocket expenses can be prohibitive, prompting treatment interruption or conversion to cheaper substitutes such as biosimilars.
The branded segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the product, the humira market is divided into branded and biosimilar. Among these, the branded segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segmental growth is due to humira has been available for more than 20 years, garnering broad acceptance among physicians and patients. Its extensive history of safety and efficacy renders it the first choice of treatment for many, which fuels high brand loyalty, particularly in the rheumatoid arthritis and inflammatory bowel disease segments.
The rheumatoid arthritis (RA) segment accounted for a significant share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period.
Based on the application, the humira market is divided into rheumatoid arthritis (RA), psoriatic arthritis (PSA), Crohn's disease (CD), ulcerative colitis (UC), ankylosing spondylitis, and others. Among these, the rheumatoid arthritis (RA) segment accounted for a significant share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. The growth is attributed to humira is very effective in lowering inflammation, relieving pain, and avoiding joint damage in RA patients. Its long history of success in treating the disease has earned it a reputation as a reliable treatment. This has resulted in widespread prescribing by physicians, earning it a place in the RA market.
North America is expected to hold the majority share of the global humira market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global humira market during the forecast period. Humira was approved by the FDA in 2002, well ahead of other countries. This early access enabled AbbVie, a biopharma, to solidify market leadership, win physician confidence, and establish a loyal patient franchise. The longer exclusivity duration in the United States further cemented its leadership, making North America the most developed and profitable market for Humira.
Asia Pacific is anticipated to grow at the fastest pace in the global humira market during the forecast period. As health systems throughout Asia-Pacific become more developed, increasing numbers of patients are being identified with autoimmune diseases like rheumatoid arthritis and Crohn's disease. Enhanced diagnostic technologies and increased physician knowledge are revealing previously undiagnosed cases. Rising detection is driving demand for sophisticated treatments like Humira, and thus, the market in the region is growing at a fast pace.
Europe is predicted to hold a significant share of the humira market throughout the estimated period. Most European nations have systems of universal coverage where there is ample access to biologics. Governments provide subsidy for costly therapies such as Humira, commonly through national health programs, and this ensures access to the drug by patients and thus supports the drug's market share.
Major vendors in the global humira market are Alvotech, Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., CELLTRION INC., Coherus BioSciences, Inc., Fresenius Kabi AG, FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., Pfizer Inc., Samsung Bioepis, Sandoz Inc., and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In April 2025, the U.S. Food and Drug Administration (FDA) approved YUFLYMA, a biosimilar of Humira (adalimumab), for use as an interchangeable product. Formulated by Celltrion, Inc., YUFLYMA is a high-concentration, citrate-free formulation designed to minimize injection pain and provide an improved patient-friendly alternative.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the humira market based on the below-mentioned segments:
Global Humira Market, By Product
- Branded
- Biosimilar
Global Humira Market, By Application
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis (PsA)
- Crohn’s Disease (CD)
- Ulcerative Colitis (UC)
- Ankylosing Spondylitis
- Others
Global Humira Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?